ISDA: 4GMY

Deposition Date 2012-08-16

Release Date 2013-06-19

Last Version Date 2024-11-20

Entry Detail

PDB ID:

4GMY

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.23

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Chain IDs:A
Chain Length:302
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	O-PHOSPHOTYROSINE

Ligand Molecules

0X5

Primary Citation

Lead identification of novel and selective TYK2 inhibitors.

Liang, J, Tsui, V, Van Abbema, A, Bao, L, Barrett, K, Beresini, M, Berezhkovskiy, L, Blair, W.S, Chang, C, Driscoll, J, Eigenbrot, C, Ghilardi, N, Gibbons, P, Halladay, J, Johnson, A, Kohli, P.B, Lai, Y, Liimatta, M, Mantik, P, Menghrajani, K, Murray, J, Sambrone, A, Xiao, Y, Shia, S, Shin, Y, Smith, J, Sohn, S, Stanley, M, Ultsch, M, Zhang, B, Wu, L.C, Magnuson, S.Show

Eur.J.Med.Chem. 67 175 187 (2013)

PMID: 23867602 DOI: 10.1016/j.ejmech.2013.03.070

Abstact

A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine 1 as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form